Clinical Trial Update: Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)

View source ↗

Summary

The Niacin/laropiprant re-examination study (TREDAPTIVE) for hypercholesterolemia and mixed dyslipidemia was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• TREDAPTIVE (niacin/laropiprant)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hypercholesterolemia, Mixed Dyslipidemia | Status: TERMINATED | Results posted: 2014-04-25